Clinical Trials
80 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
AZUR-1
GlaxoSmithKline
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
H. Lee Moffitt Cancer Center and Research Institute
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Organ Preservation in Early Rectal Cancer Patients
Fox Chase Cancer Center
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
REGINA
Jules Bordet Institute
AMPLIFY-7P
Elicio Therapeutics
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Institutes of Health Clinical Center (CC)
TTBF
University of California, San Francisco
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
RAPIDO
University Medical Center Groningen
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
National Cancer Institute (NCI)
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
University of Aarhus
KRYSTAL-10
Mirati Therapeutics Inc.
Supportive Oncology Care At Home RCT
Massachusetts General Hospital
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision
Chang Gung Memorial Hospital
Multicenter Phase II Study of Transanal TME (taTME)
Icahn School of Medicine at Mount Sinai
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
OHSU Knight Cancer Institute
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Providence Health & Services
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Sun Yat-sen University
SEAMARK
Pfizer
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
TOWER-1
Sun Yat-sen University
SOLAR
Kyungpook National University Hospital
SYLVER
GlaxoSmithKline
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
Memorial Sloan Kettering Cancer Center
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
Rabin Medical Center
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
RCT of Mobile Apps & FitBit v. Usual Care
Weill Medical College of Cornell University
Neo-IT
Sir Run Run Shaw Hospital
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
The First Affiliated Hospital of Anhui Medical University
Colon Neoadjuvant FOLFOXIRI Study
Chinese University of Hong Kong
FOLFOXIRI With or Without Intensification for Rectal Cancer
Chinese University of Hong Kong
China AZUR-1
GlaxoSmithKline
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
OPERA
Centre Antoine Lacassagne
SCOTCH
Tata Memorial Centre